Literature DB >> 9104591

Increased expression of trkB mRNA in rat caudate--putamen following 6-OHDA lesions of the nigrostriatal pathway.

S Numan1, K B Seroogy.   

Abstract

The tyrosine kinase receptors trkB and trkC are essential components of the high-affinity receptors for members of the neurotrophin family, including brain-derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3). Both neurotrophin receptor mRNAs are broadly distributed throughout the caudate-putamen. In animal models of Parkinson's disease, loss of the ventral mesencephalic dopamine projection to the striatum has been shown to alter the expression of several striatal peptides, neurotransmitter-synthesizing enzymes and receptors. To determine if expression of trkB and/or trkC striatal mRNAs is also regulated by the integrity of the dopaminergic afferents, adult rats were given unilateral injections of 6-hydroxydopamine (6-OHDA), a selective catecholamine neurotoxin, or vehicle into the right ascending medial forebrain bundle. Following a 2 week survival period, in situ hybridization with 35S-labelled cRNA probes for the kinase-specific, full-length form of trkB mRNA and all forms of trkC mRNA was performed in striatal sections. A significant increase in the hybridization density for trkB mRNA was observed in the caudate-putamen ipsilateral to the 6-OHDA injection, compared with the uninjected control side (P < 0.001). In contrast, no alteration in the hybridization density for trkC mRNA was observed in the striatum of 6-OHDA-treated rats. No alterations in trkB or trkC mRNA levels were observed in the striata of vehicle-treated animals. These data suggest that midbrain dopaminergic afferents regulate the expression of trkB mRNA in the caudate-putamen. Alternatively, since dopaminergic neurons of the ventral mesencephalon express BDNF mRNA, the up-regulation of striatal trkB mRNA may reflect a compensatory response by striatal neurons due to a loss of anterogradely and/or retrogradely derived trophic support from the ventral midbrain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9104591     DOI: 10.1111/j.1460-9568.1997.tb01626.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  8 in total

1.  Regulation of phospholipase Cgamma in the mesolimbic dopamine system by chronic morphine administration.

Authors:  D H Wolf; S Numan; E J Nestler; D S Russell
Journal:  J Neurochem       Date:  1999-10       Impact factor: 5.372

2.  (±)3,4-methylenedioxymethamphetamine ("ecstasy") treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain.

Authors:  Ann M Hemmerle; Jonathan W Dickerson; Nicole R Herring; Tori L Schaefer; Charles V Vorhees; Michael T Williams; Kim B Seroogy
Journal:  J Comp Neurol       Date:  2012-08-01       Impact factor: 3.215

3.  Developmental expression of neurotrophins and their receptors in postnatal rat ventral midbrain.

Authors:  Suzanne Numan; Christine M Gall; Kim B Seroogy
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor.

Authors:  B A Horger; C A Iyasere; M T Berhow; C J Messer; E J Nestler; J R Taylor
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

5.  Differential regulation of neurotrophin and trk receptor mRNAs in catecholaminergic nuclei during chronic opiate treatment and withdrawal.

Authors:  S Numan; S B Lane-Ladd; L Zhang; K H Lundgren; D S Russell; K B Seroogy; E J Nestler
Journal:  J Neurosci       Date:  1998-12-15       Impact factor: 6.167

Review 6.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

7.  The cortical and striatal gene expression profile of 100 hz electroacupuncture treatment in 6-hydroxydopamine-induced Parkinson's disease model.

Authors:  Li-Rong Huo; Xi-Bin Liang; Bo Li; Jian-Tao Liang; Yi He; Yan-Jun Jia; Jun Jia; Xiao-Li Gong; Fen Yu; Xiao-Min Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-01-26       Impact factor: 2.629

8.  Alterations of BDNF and trkB mRNA expression in the 6-hydroxydopamine-induced model of preclinical stages of Parkinson's disease: an influence of chronic pramipexole in rats.

Authors:  Klemencja Berghauzen-Maciejewska; Jadwiga Wardas; Barbara Kosmowska; Urszula Głowacka; Katarzyna Kuter; Krystyna Ossowska
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.